Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
To evaluate the time to treatment intervention in patients with Parkinson's Disease (PD),
Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Non-Diabetic Autonomic
Neuropathy (NDAN) or Dopamine Beta Hydroxylase (DBH) Deficiency who have been previously
stabilized with droxidopa therapy for symptoms of neurogenic orthostatic hypotension (NOH)
(dizziness, light-headedness, or feelings that they are about to black out)